Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26548580 | 0.79 | — | — | |
| SCHEMBL244234 | 0.77 | PGR (0.33) | PGR | |
| SCHEMBL12975276 | 0.76 | — | — | |
| SCHEMBL5131293 | 0.75 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL6037103 | 0.74 | — | — | |
| SCHEMBL1661515 | 0.74 | EPHX1 (0.33) | — | |
| SCHEMBL22928259 | 0.74 | PGR (0.33) | PGR | |
| SCHEMBL10309464 | 0.74 | PGR (0.33) | PGR | |
| SCHEMBL10153813 | 0.74 | PTGS1 (0.33) | — | |
| SCHEMBL4209727 | 0.74 | CA2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332008-A1 | PHENOL COMPOUND, CONDUCTIVE PASTE COMPOSITION, METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| WO-2017132021-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2017-08-03 | — | — | WO | disclosed |
| EP-2506716-B1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9593115-B2 | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof | ADVINUS THERAPEUTICS LTD. | 2017-03-14 | — | — | US | disclosed |
| US-9593115-B2 | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof | ADVINUS THERAPEUTICS LTD. | 2017-03-14 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9353116-B2 | Methods and compositions for kinase inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150239886-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-27 | — | — | US | disclosed |
| US-20150239886-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2015-08-27 | — | — | US | disclosed |
| US-7629468-B2 | Neuroprotectants, analgesics or anticonvulsants | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-08 | — | — | US | disclosed |
| US-7517517-B2 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-7517517-B2 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035267-A1 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1332133-B1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008019266-A2 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008019303-A2 | PYRIDAZINONYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008002924-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007084595-A2 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | PRSS1, SPINT2, TMPRSS4 | PGR 1611/4885 |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | JAK1, JAK2, JAK3 | PGR 1627/4885 |
| US-20150239886-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | JAK1, MALT1, JAK2 | PGR 1652/4885 |
| US-20090035267-A1 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, HPN | PGR 1653/4885 |
| US-20230332008-A1 | PHENOL COMPOUND, CONDUCTIVE PASTE COMPOSITION, METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION, CONDUCTIVE WIRE, AND METHOD FOR PRODUCING CONDUCTIVE WIRE | COL1A1, MYB, HES1 | PGR 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.